生物模拟市场：依产品/服务、应用和最终用户划分 - 全球预测至 2036 年

全球生物模拟市场预计将以 16.5% 的复合年增长率成长，从 2026 年的 61.5 亿美元增长到 2036 年的约 285 亿美元。

本报告对五大主要地区的生物模拟市场进行了详细分析，重点关注当前市场趋势、市场规模、近期发展以及至 2036 年的预测。透过广泛的二级和一级研究以及对市场现状的深入分析，我们对关键产业驱动因素、限制因素、机会和挑战进行了影响分析。

推动生物模拟市场成长的关键因素包括：全球对精准医疗的日益重视、电脑辅助药物开发的快速发展、严格的监管要求以及降低测试成本的需求。 此外，人工智慧 (AI) 和机器学习的快速普及、对高性能药物动力学和药效动力学建模的需求不断增长、计算效率的提高以及数位转型 (DX) 的推动，预计将为生物模拟市场中的公司创造巨大的成长机会。

市场区隔

目录

第一章：引言

第二章：摘要整理

第三章：市场概览

• 市场动态
  • 驱动因素
  • 限制因素
  • 机遇
  • 挑战
• 市场趋势
  • 热门数位孪生与人工智慧整合
  • 云原生与多模态研究平台的创新
  • 拓展至罕见疾病及孤儿药领域
• 监理框架与标准
• 波特五力分析
• PESTEL分析
• 价值链分析

第四章 全球生物模拟市场（依产品及服务划分）

• 软体
  • 分子建模与模拟软体
  • PBPK建模软体
  • PK/PD建模软体
  • 研究设计软体
  • 毒性预测软体
• 服务
  • 内部服务
  • 合约服务

第五章 全球生物模拟市场（依应用划分）

• 药物开发
  • 临床前开发
  • 临床试验
• 药物发现
  • 标靶识别
  • 先导化合物优化
• 个人化医疗
• 医疗器材发展
• 其他

第六章 全球生物模拟市场（依最终用户划分）

• 製药和生技公司
• 合约研究组织 (CRO)
• 学术和研究机构
• 监理机构

第七章 全球生物模拟市场（依地区划分）

• 北美
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 瑞士
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 其他亚太地区
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 智利
  • 哥伦比亚
  • 其他南美国家各国
• 中东·非洲
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非
  • 埃及
  • 以色列
  • 其他中东和非洲

第8章 竞争情形

• 市场占有率分析
• 竞争仪表板
  • Industry Leader
  • Market Differentiators
  • Vanguards
  • Emerging Companies
• 最近的策略性趋势

第9章 企业简介

• Certara, Inc.
• Simulations Plus, Inc.
• Dassault Systemes(BIOVIA)
• Schrodinger, Inc.
• Genedata AG
• Physiomics plc
• Rosa &Co. LLC
• BioSimulation Consulting Inc.
• InSilico Trials Technologies
• Aitia
• VeriSIM Life
• SimBioSys

第10章 附录

Biosimulation Market by Product & Service (Software, Services), Application (Drug Development, Drug Discovery, Personalized Medicine, Others), and End User (Pharmaceutical & Biotechnology Companies, CROs, Academic & Research Institutes) - Global Forecast to 2036

According to the research report titled, 'Biosimulation Market by Product & Service (Software, Services), Application (Drug Development, Drug Discovery, Personalized Medicine, Others), and End User (Pharmaceutical & Biotechnology Companies, CROs, Academic & Research Institutes) - Global Forecast to 2036,' the global biosimulation market is expected to reach approximately USD 28.50 billion by 2036 from USD 6.15 billion in 2026, at a CAGR of 16.5% during the forecast period (2026-2036).

The report provides an in-depth analysis of the global biosimulation market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.

The major factors driving the growth of the biosimulation market include the intensifying global focus on precision medicine, rapid expansion of in-silico drug development, stringent regulatory requirements, and the need to reduce trial costs. Additionally, the rapid expansion of artificial intelligence and machine learning, increasing need for high-performance pharmacokinetic and pharmacodynamic modeling, advanced computational efficiency, and digital transformation initiatives are expected to create significant growth opportunities for players operating in the biosimulation market.

Market Segmentation

The biosimulation market is segmented by product & service (software, services), application (drug development, drug discovery, personalized medicine, others), end user (pharmaceutical & biotechnology companies, CROs, academic & research institutes), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Product & Service

By product & service, the software segment holds the largest market share in 2026, primarily attributed to its support for molecular modeling, complex diagnostics, and trial design in diverse research environments. These platforms offer comprehensive capabilities for predictive modeling and simulation. However, the services segment is expected to grow at a rapid CAGR during the forecast period, driven by the growing need for contract research, implementation support, and specialized consulting services. The ability to provide integrated solutions with expert support makes services highly attractive for modern pharmaceutical infrastructure.

Based on Application

By application, the drug development segment holds the largest share of the overall market in 2026, primarily due to its proven efficacy in handling high-volume clinical trial projects and providing scalable, performance-optimized solutions. The personalized medicine segment is expected to witness the fastest growth during the forecast period, driven by the shift toward precision medicine approaches, genomic analysis integration, and the complexity of advanced personalized treatment requirements. Both segments represent distinct operational requirements and technological specifications.

Based on End User

By end user, the pharmaceutical & biotechnology companies segment holds the largest share of the overall market in 2026, due to their superior data management capacity, high-performance systems, and extensive R&D investments. The CROs segment is expected to grow at a significant CAGR during the forecast period, driven by increased demand for outsourced research services, commercial logistics support, and specialized formulation expertise. Academic & research institutes represent an emerging segment with growing adoption of biosimulation tools for research and training purposes.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global biosimulation market with the largest market share, primarily attributed to massive investments in biotech R&D and the presence of leading technology innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by aggressive digital transformation initiatives and rapid adoption of advanced clinical services in China, India, and Japan. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing pharmaceutical R&D investments and increasing demand for advanced biosimulation technologies.

Key Players

The key players operating in the global biosimulation market are Certara USA Inc., Simulations Plus Inc., Schrodinger Inc., Schrodinger, Genedata AG, Rhenovia Pharma, Entellus Consulting, Exscientia Ltd., Cyclica Inc., Atomwise Inc., and various other regional and emerging manufacturers, among others.

Key Questions Answered in the Report-

• What is the current revenue generated by the biosimulation market globally?
• At what rate is the global biosimulation market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the global biosimulation market?
• What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of product & service, application, and end user are expected to create major traction for the service providers in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global biosimulation market?
• Who are the major players in the global biosimulation market? What are their specific service offerings in this market?
• What are the recent strategic developments in the global biosimulation market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Biosimulation Market Assessment -- by Product & Service

• Software
• Services

Biosimulation Market Assessment -- by Application

• Drug Development
• Drug Discovery
• Personalized Medicine
• Others

Biosimulation Market Assessment -- by End User

• Pharmaceutical & Biotechnology Companies
• CROs (Contract Research Organizations)
• Academic & Research Institutes

Biosimulation Market Assessment -- by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Scope
• 1.3. Research Methodology
• 1.4. Assumptions & Limitations

2. Executive Summary

3. Market Overview

• 3.1. Introduction
• 3.2. Market Dynamics
  • 3.2.1. Drivers
  • 3.2.2. Restraints
  • 3.2.3. Opportunities
  • 3.2.4. Challenges
• 3.3. Market Trends
  • 3.3.1. Proliferation of Digital Twins and AI Integration
  • 3.3.2. Innovation in Cloud-Native and Multi-Modal Research Platforms
  • 3.3.3. Expansion into Rare Diseases and Orphan Drugs
• 3.4. Regulatory Framework and Standards
• 3.5. Porter's Five Forces Analysis
• 3.6. PESTEL Analysis
• 3.7. Value Chain Analysis

4. Global Biosimulation Market, by Product & Service

• 4.1. Introduction
• 4.2. Software
  • 4.2.1. Molecular Modeling & Simulation Software
  • 4.2.2. PBPK Modeling Software
  • 4.2.3. PK/PD Modeling Software
  • 4.2.4. Trial Design Software
  • 4.2.5. Toxicity Prediction Software
• 4.3. Services
  • 4.3.1. In-house Services
  • 4.3.2. Contract Services

5. Global Biosimulation Market, by Application

• 5.1. Introduction
• 5.2. Drug Development
  • 5.2.1. Preclinical Development
  • 5.2.2. Clinical Trials
• 5.3. Drug Discovery
  • 5.3.1. Target Identification
  • 5.3.2. Lead Optimization
• 5.4. Personalized Medicine
• 5.5. Medical Device Development
• 5.6. Others

6. Global Biosimulation Market, by End User

• 6.1. Introduction
• 6.2. Pharmaceutical & Biotechnology Companies
• 6.3. Contract Research Organizations (CROs)
• 6.4. Academic & Research Institutes
• 6.5. Regulatory Authorities

7. Global Biosimulation Market, by Geography

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. U.S.
  • 7.2.2. Canada
• 7.3. Europe
  • 7.3.1. Germany
  • 7.3.2. UK
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Switzerland
  • 7.3.7. Rest of Europe
• 7.4. Asia-Pacific
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. India
  • 7.4.4. South Korea
  • 7.4.5. Australia
  • 7.4.6. Rest of Asia-Pacific
• 7.5. Latin America
  • 7.5.1. Brazil
  • 7.5.2. Mexico
  • 7.5.3. Argentina
  • 7.5.4. Chile
  • 7.5.5. Colombia
  • 7.5.6. Rest of Latin America
• 7.6. Middle East & Africa
  • 7.6.1. Saudi Arabia
  • 7.6.2. UAE
  • 7.6.3. South Africa
  • 7.6.4. Egypt
  • 7.6.5. Israel
  • 7.6.6. Rest of Middle East & Africa

8. Competitive Landscape

• 8.1. Introduction
• 8.2. Market Share Analysis
• 8.3. Competitive Dashboard
  • 8.3.1. Industry Leader
  • 8.3.2. Market Differentiators
  • 8.3.3. Vanguards
  • 8.3.4. Emerging Companies
• 8.4. Recent Strategic Developments

9. Company Profiles

• 9.1. Certara, Inc.
• 9.2. Simulations Plus, Inc.
• 9.3. Dassault Systemes (BIOVIA)
• 9.4. Schrodinger, Inc.
• 9.5. Genedata AG
• 9.6. Physiomics plc
• 9.7. Rosa & Co. LLC
• 9.8. BioSimulation Consulting Inc.
• 9.9. InSilico Trials Technologies
• 9.10. Aitia
• 9.11. VeriSIM Life
• 9.12. SimBioSys

10. Appendix